Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
“We published a reflective article on why the uptake of gene therapy in hemophilia is less than expected. It’s not due to lack of interest in gene therapy in general by patients and health care providers, as some have alleged, but related to more complex problems including the differing benefit/risk balance of individual gene therapies and need for more creative reimbursement frameworks. Medicines with strong efficacy and safety have been, and will continue to be embraced by the community. We look forward to advancing technological improvements in gene therapies, including gene editing, especially for hemophilia A, and to more enthusiasm of biopharma to reach 85% of the world having substandard or no treatment.”
To learn more, follow the link.
Read the full article here.
Article: Why is the uptake of gene therapy in hemophilia less than expected?
Authors:
Stay updated on the latest scientific advancements in the field of hemophilia with Hemostasis Today.
-
Jan 8, 2026, 05:51Dominika Jędrzejewska Akbaş Links Sleep Deprivation, Obesity, and Stroke
-
Jan 8, 2026, 05:42Rob Maloney: A Bruise that Did Not Go Away…
-
Jan 8, 2026, 05:33Matías J Alet on Treating Early Neurological Deterioration in Lacunar Stroke
-
Jan 8, 2026, 05:11Thomas Meinel Shares The English Stroke Guidelines 2026
-
Jan 8, 2026, 05:03Hilla Ben-Pazi: We Were Pleased to Receive a Grant from the Israeli Ministry of Economy
-
Jan 8, 2026, 04:24Nikhil Agrawal Breaks Down Perioperative Anticoagulation
-
Jan 8, 2026, 03:58Louise St Germain Bannon Appointed Interim Executive Director of ISTH
-
Jan 8, 2026, 03:47Wolfgang Miesbach on Fernando Corrales-Medina’s Team’s Latest Cross-Sectional Study on Haemophilia
-
Jan 8, 2026, 03:28Rick Matthews: Powerful Perspective from Erin and the NBCA Team